Table 2 Antiretroviral therapy prior to nevirapine-containing regimen
From: Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children
PATIENT | AGE at 1st regimen | Mono-therapy | Dual-therapy | Cumulative duration | HAART | Cumulative duration | CD4% | Viral load cop/ml |
|---|---|---|---|---|---|---|---|---|
months | NRTI | NRTI | NRTI | PI | PI | 0–12 months | 0–12 months | |
D4T-3TC- | AMP(36 m)+ | |||||||
1 | 119 | NO | ZDV-DDI | 27 | AMP+RIT | RIT (6 m) | 33–41 | 50–50 |
2 | 39 | NO | ZDV-DDI | 36 | D4T-3TC-AMP | AMP(48 m) | 32–30 | 50–50 |
3 | 65 | NO | NO | 0 | ZDV-DDI-RIT | RIT(32 m) | 29–34 | 50–50 |
4 | 14 | ZDV | ZDV-DDI | 19+21 | D4T-3TC-NFV | NFV(56 m) | 42–44 | 50–50 |
5 | 92 | NO | NO | 0 | ZDV-ABC-IND | IND(28 m) | 34–30 | 50–50 |
6 | 9 | ZDV/DDI | NO | 109 | ZDV-DDI-IND | IND(60 m) | 32–27 | 50–10325 |
7 | 6 | ZDV | NO | 92 | ZDV-3TC-IND | IND(52 m) | 31–34 | 50–50 |
33%(29,42) | ||||||||
median | 53 m (6,119) | 52 m (0,109) | 130 m (99,177) | 47 m (28,60) | 37%(27,44) | 50 |